Monro: A Control Fight With a Date On It

What is his average price, and what number does he have to say yes to?

Everyone quotes the panic-day fills of $14 to $15. That is not his basis. Item 3 of the 13D states the total: 4,439,914 shares purchased for approximately $84.7 million. The 60-day transaction table only accounts for 2,974,914 of them. Subtract and the arithmetic falls out:

His blended average is $18.86. At $12.33 the position is worth $62.6M against $95.8M of cost. He is down $33.2M, or 34.6%, on the common alone.

Then add the swaps. 16.5% of economic exposure is about 5.16M share equivalents. Struck anywhere in the $15 to $18 range, those carry another $14M to $29M of mark-to-market loss, plus a financing cost he pays every day they stay open. Call it $45M to $65M underwater in total, with roughly $19 required to break even on the common.

That is his reservation price, and it explains the last nine months. A $16 bid does not clear. He cannot be bought out here without booking a loss, and the pill will not let him average down. So he does nothing, files nothing, and waits for November 6.

One filing note: the amendment dates its three purchases October 5, 6 and 7, but October 5, 2025 was a Sunday with no trading, the amendment's own cover reports an event date of November 6, and the prices of $17.23 to $17.48 sit inside the November 5 to 7 range. The trades are almost certainly November 5 to 7.

Has a single insider bought a share? No

Thirty-six Forms 4 have been filed since August 2025. Zero contain an open-market purchase. Every acquisition is transaction code A at $0.00, meaning a grant. The batch filed on August 12 and 13, 2026, which looks like insider activity on a screen, is the annual director restricted stock grant: 11,149 shares each, awarded August 11, at zero cost.

The stock went from $18 to $11 and not one director or officer bought it. Directors were handed stock the same week the shares hit a 52-week low and none of them added a dollar of their own. In a situation where the entire thesis is "the people running this know it is worth far more," that is the cleanest contrary signal available.

Is the goodwill about to be written off? Probably

There is $736.4M of goodwill sitting against a $386M market capitalisation and $583M of book equity. The market is valuing the whole company at about half its goodwill.

The 10-K discloses that this already happened once: "during the fourth quarter of 2026, we experienced a decline in our market capitalization… we viewed this event as a triggering event and performed a quantitative analysis of the fair value of the Company's single reporting unit as of March 28, 2026 which resulted in an estimated fair value that exceeded its carrying value." They passed. They never disclosed by how much. The stock was $15.47 that day. It is 20% lower now.

The tell is in the credit agreement. The Fifth Amendment specifically modified the EBITDAR definition "to permit add-backs relating to non-cash impairment." The banks wrote the escape hatch before the company needed it. An impairment changes no cash, but it takes tangible book from −$161M to somewhere near −$900M, and it makes the "just refinance it" branch of the strategic review considerably harder to sell.

Where does the balance sheet actually break?

Not at the leverage covenant. Adjusted debt to EBITDAR is running "a bit over 3" against a 4.75x cap, and minimum interest coverage was just cut from 1.55x to 1.25x. The binding constraint is the dividend gate.

The credit facility has been amended six times, with covenant relief bought in May 2024, May 2025 and again in May 2026. The facility itself has been cut $600M → $500M → $400M. The spread went from SOFR plus 10 basis points to SOFR plus 225. Buybacks are prohibited outright while the revolver is drawn. And dividends now require minimum liquidity of $200M, with the covenant cushion tightened from 0.50x to 0.25x.

Liquidity at June 27 was $261M of availability plus $10M of cash, so $271M against a $200M floor. One more quarter like the last one puts them within about $30M of the gate. That is where the dividend goes, and it goes well before any covenant trips. Facility matures November 10, 2027, which is the real reason a process is running at all.

Who is actually paying for the turnaround, and what is it costing?

This is not in any of the coverage. The current CEO was placed by a restructuring firm: he was a partner and managing director of that firm until December 2025, having been appointed CEO in March 2025 under an engagement letter with its affiliate. The proxy discloses the related party transaction.

Through fiscal 2026 the company paid that firm and its affiliate $20.2M and $2.1M respectively. That is $22.3M of consulting fees in a single year at a company whose entire fiscal 2026 operating income was $15M. The Q1 FY27 expense bridge quietly notes "$3.7 million of lower costs incurred in connection with consultants" as a favourable variance, which tells you the run rate is still material.

An acquirer strips that out on day one. It is also a reasonable thing for a shareholder to be annoyed about, and it is probably part of why the withhold vote landed where it did.

Does the tire supply contract survive a change of control?

In 2023 Monro sold its distribution centres and internal tire distribution operations to a national tire distributor for $102M, and signed a distribution agreement in the other direction. Company-operated stores must purchase at least 90% of their forecast requirements for passenger car, light truck and medium truck tires through that distributor. The initial term runs to January 1, 2030, with automatic twelve-month renewals.

Every plausible strategic buyer has its own distribution network and its own vendor economics. A buyer either eats the contract for four more years, negotiates out of it, or pays less for Monro because of it. It is a live diligence item that nobody is modelling and it is a genuine friction on the takeout price.

Who can actually buy this, and does the obvious buyer have capacity?

The obvious buyer just spent $700M of cash and is now at 4,400+ locations concentrated in the Northeast and Mid-Atlantic. Monro's largest states are New York (134), Ohio (107), Pennsylvania (106), Florida (101), California (94), Maryland (65) and Virginia (65). The overlap is heavy. A second same-category, same-corridor roll-up inside twelve months is not an antitrust formality.

The realistic alternatives: the sponsor-backed tire and service platforms, the large regional tire retailers, and the tire manufacturer that lost the 2016 Pep Boys auction and has since been rationalising its own retail footprint. Financial sponsors also work here, because 290 owned sites fund a meaningful slice of the equity cheque through sale-leaseback.

And the break-up: regional lots sold to several buyers. That is probably the highest-price and longest-timeline outcome, and it requires a board that wants it.

Why did the review announcement close down on the day?

Because of who is advising. One of the two financial advisors is a boutique investment bank founded and chaired by a sitting Monro director, a man who has been on the board since 1984 and whose family's preferred stock, carrying a 60% veto over all common shareholder action, converted into common three weeks after the review was announced. He also sits on the Executive Committee.

None of that is improper and the proxy discloses the relationship. But it is not the look of a clean arm's-length auction, and a market that has watched this board defend itself with a pill was never going to pay full deal odds for it.

What is the floor if the review ends in "operational improvements"?

Post-sale-leaseback EBITDA of about $63M at 6x is $378M of OpCo enterprise value. Add $290M of real estate, subtract $99M of net bank debt and $221M of finance leases: $348M of equity, or $11.14 a share. That assumes the dividend survives. It also assumes no goodwill impairment shakes confidence further.

Cut the dividend and the income holders leave a stock with negative tangible book, four years of declining revenue and a facility maturing in 2027. Single digits is reachable. The 52-week low of $11.06 was set six days ago.

What happens on November 7 if nothing happens?

Three branches. He buys freely through 17.5% and keeps going. He unwinds swaps into physical shares toward the low thirties. Or the board adopts a new pill, which New York law permits and which costs them nothing legally.

The only real check on branch three is political: the 40% withhold against the Chairman, and the awkwardness of re-arming against a holder of a third of the economics while your own bankers are supposedly running a sale. It is a check, not a prohibition. Anyone underwriting "the pill expires and something must happen" should price the renewal branch at meaningfully more than zero.

If the board stonewalls, what is the actual escalation path and when does it run?

This is the part that makes the pill expiry matter rather than just being a date. The company moved to annual election of all directors in 2025. There is no staggered board left to slow anyone down. Every seat is up every year, which means one proxy contest can replace the entire board in a single meeting.

The proxy discloses the advance-notice window. For the 2027 annual meeting, director nominations must be delivered no earlier than February 11, 2027 and no later than April 12, 2027, assuming the meeting is held on or around August 10, 2027. Miss that window and he waits another full year.

Line the dates up and the pressure sequence is almost perfectly engineered:

A board that refuses to sell in 2026 faces a shareholder vote it can lose in August 2027, conducted by a holder of a third of the economics, with a debt maturity landing twelve weeks after the votes are counted. That is why the process exists, and it is the strongest argument that this ends in a transaction rather than a stalemate. It is also why the realistic timeline runs into 2027, not this autumn.

What is the real estate actually carried at, rather than guessed at?

My $290M estimate above was a per-site assumption. The 10-K gives a harder anchor. Gross property and equipment at March 28, 2026 breaks down as:

Spread across 290 owned sites plus 42 owned buildings on leased land, that is roughly $1.13M of gross historical cost per property. And the land line is the important one: $75.5M carried at cost, or about $227K a site, in money spent across three decades of roll-up acquisitions. Land is never depreciated and almost never written up, so book is a floor, not an estimate.

This makes the $290M real estate credit look conservative rather than aggressive, and it means the sale-leaseback branch of the strategic review is a real financing option, not a talking point. Note also that land at cost fell from $83.8M to $75.5M during fiscal 2026 as closed stores were sold, with 37 properties still to be monetised.

Who exactly is accountable, and does the record explain the 40% withhold?

It does, and it is more specific than "long tenure." The director who drew 40.4% withheld is the Chairman of the Board, age 82, on the board since 2010, chair of the Nominating and Corporate Responsibility Committee, a member of the Compensation Committee, and the company's own interim CEO from August 2020 to April 2021. He presided over the period the business began shrinking, chose the committee that recruited the current management, and sits on the committee that pays them.

Add the arrangement described in Question 05: the CEO was engaged in March 2025 through a restructuring firm's affiliate and was not directly employed by the company until December 2, 2025, roughly eight months into the job, while that firm collected $22.3M of fees in the same fiscal year. Whatever the merits, a shareholder looking for someone to hold responsible for the last three years has an unusually clear target, and roughly a third of the register found it.

What is the single tell that separates a real process from theatre?

A 13D amendment. There has not been one since November 7, 2025. Nine months of silence is itself information: he is boxed by the pill and waiting for the calendar. Every meaningful development, a swap unwind, an open-market purchase, a formal proposal, a standstill, a settlement, or board seats, has to be filed there within two business days. That document is the whole scoreboard and it is free to watch.

Second tell: any 8-K amending or redeeming the rights agreement before November 6. Early redemption means a deal is signed or close. Silence through November 6 means the board let it lapse rather than defend, which is its own signal.

Is the July working capital reversal actually verifiable, and when?

Yes, and it is the cleanest near-term falsifier in the whole thesis. Management committed on the record that working capital will "largely retrace over the next couple quarters" and will not be a significant use of cash for the full year. The September-quarter 10-Q, filed in late October, will show it or it will not.

Two things to check when it lands: does accounts payable to inventory recover from 185% back toward 200%, and does the revolver balance come back down from $108.4M. If operating cash flow is negative again and the revolver is above $130M, the working capital explanation was wrong, the dividend is gone within two quarters, and the floor case becomes the base case.